Genetically modified cells have been shown to be one of the most effective cancer vaccine strategies. An evaluation is made of the efficacy of both preventive and therapeutic antitumor vaccines against murine melanoma, using C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells. In preventive vaccination, all treated groups showed delayed tumor growth. In addition, the group vaccinated to express only GM-CSF achieved 100% animal survival (Po0.005). Vaccination with GM-CSF þ IL-12-producing B16 cells yielded lesser results (60% survival, Po0.005). Furthermore, all surviving animals remained disease-free after second tumor implantation 1 year later. The therapeutic vaccination strategies resulted in significantly delayed tumor growth, mainly using B16 cells producing GM-CSF þ IL-12 cytokines, with 70% tumor growth inhibition (Po0.001)-although none of the animals reached overall survival. The results obtained suggest that the GM-CSF þ IL-12 combination only increases the efficacy of therapeutic vaccines. No differences in classical regulatory T cells were found among the different groups.
INTRODUCTION
Immunotherapy has become a genuine alternative to conventional cancer treatment based on surgery, radiotherapy and chemotherapy. Melanoma is possibly the best candidate for immunotherapy as an alternative to current treatments, because it is a very immunogenic type of malignancy. 1 In the field of immunotherapy, antitumor vaccines are a promising therapeutic strategy to induce the immune system to specifically target tumor cells. Antitumor vaccines with genetically modified tumor cells have already proven to be effective in application to some types of cancer in animal models, [2] [3] [4] [5] [6] [7] and some of them are being tested in clinical trials. [8] [9] [10] [11] [12] Some cytokines, such as interferon-a or interleukin-12 (IL-2), are used in the clinical setting as adjuvants in some types of cancer. The cytokine GM-CSF (granulocyte and macrophage colonystimulating factor) has demonstrated a very important antitumor effect. 2, [6] [7] [8] [9] [10] 13 Another well-known cytokine that has shown antitumor effects is IL-12.
1, [14] [15] [16] [17] [18] [19] However, the signaling pathways of the immune system are very complex, and in the last few years many studies have tested different combinations of cytokines with other molecules in order to improve antigen presentation, such as for instance GM-CSF and IL-12. [20] [21] [22] [23] [24] The order of antigen and cytokine presentation is critical for the success of antitumor response, as previous studies in our laboratory have shown using a model of preventive vaccination against murine melanoma. The best results were obtained when featuring tumor antigens first, and then the cytokine, or both simultaneously. 7 In addition, it has been proven that the vaccination was most effective when the cytokine was produced by the same genetically modified tumor cell rather than administered independently. 25 For this reason, we decided to use genetically modified cells in our cancer vaccine model. Along with other groups, we have previously achieved total survival of B16 melanoma-bearing mice in preventive vaccine models using freshly gm-csf-transfected B16 cells. 6, 7 Now we aimed to take advantage of the fact that IL-12 has also already demonstrated its usefulness in some antitumor vaccine models. We thus transfected B16 cells with a bicistronic plasmid containing both gm-csf and il-12 genes.
This study describes the efficacy of the GM-CSF or IL-12-transfected cells vaccine, and the effect of the combination of both cytokines, with the aim of determining whether there is some kind of synergy between them. This has been done by assessing efficacy in an antitumor cell preventive vaccine, although also assuming the challenge of a therapeutic vaccination. The importance of the amount of antigen and cytokine in relation to the antitumor response has also been evaluated, using vaccines with different doses of tumor-transfected cells. Finally, a study of the presence of classical regulatory T cells (Treg) in the setting of the therapeutic vaccine has also been made, in order to try to clarify whether these cells are responsible for the failure of the antitumor immune response once the tumor has become established.
MATERIALS AND METHODS Plasmids
All the p2F plasmids used were derived from the pVITRO2 base plasmid (Invivogen, Toulouse, France), using the empty plasmid (p2F-Ø), or with inserted mgm-csf and mil-12 genes. pVITRO2 allows the coexpression of two genes and contains two human ferritin composite promoters, FerH (heavy chain) and FerL (light chain), combined to the SV40 and CMV enhancers, respectively, and the resistance to hygromycin gene.
Cells and transfection procedure B16 murine melanoma cells were used in all of the experiments. These cells are syngeneic with the animals used for vaccination, that is, C57BL/6 mice (Harlan, Gannat, France).
The B16 cells used for the vaccines were transfected by means of a chemical procedure based on PEI 25 kDa (polyethyleneimine, Sigma, Madrid, Spain) polyplexes (DNA:PEI, 1:1.41) with 20 mg ml of plasmids, as previously described. 6, 26 The transfection percentage with this method lies between 20 and 40% of total cells, as observed using the reporter enhanced green fluorescent protein gene (data not shown). Cells were transfected when 480% confluence was reached in their flasks. After transfection, we waited for 72 h to irradiate the tumor cells with 150 Gy, and then froze them in dimethylsulphoxide 5% in fetal bovine serum, with storage at À 80 1C or À 150 1C until use.
ELISA
Cytokine expression ELISA. GM-CSF and IL-12 production from the transfected B16 cells was determined by enzyme linked immunosorbent assay (ELISA) performed on supernatant samples of the culture media taken 72 h post-transfection and before cell detachment and irradiation, having changed the media every 24 h. The BD OptEIA ELISA kit for mGM-CSF and mIL-12 (Pharmingen, BD Biosciences, Madrid, Spain) were used. A timepoint of 72 h was chosen on the basis of prior experimental results, assessed to study cytokine production over time, using the referred transfection conditions, 6, 7, 26 in order to guarantee adequate GM-CSF production according to the literature, that is, 435 ng per 10 6 cells per 24 h. 13, 27 Specific anti-TMP IgG ELISA. Measurement of immunoglobulin G (IgG) and of the IgG1 and IgG2a subtype antibodies against tumor membrane proteins (TMPs) was performed in serum samples by specific ELISA, as previously described. 7, 28 TMP is an extract of the hydrophilic membrane proteins of the irradiated B16 cells; thus, with this ELISA we tested the specific response to our vaccine treatment, discarding any other nonspecific immune responses.
All samples were assayed in duplicate, allowing estimation of the mean optical density value and s.d.
Preventive vaccination procedure C57BL/6 mice (8-10 weeks old) kept under standard laboratory conditions were housed five mice per cage. The experimental project was approved by the Biological Research Committee of the University of Valencia (Valencia, Spain). In all cases, mice were vaccinated subcutaneously (right leg) with a single dose per week, in weeks À 3, À 1 and þ 1 (days À 21, À 7 and þ 7), with respect to tumor injection (day 0) with 10 5 wild-type B16 cells in the left leg. The number of cells used in each vaccine dose was 2 Â 10 5 cells per mouse or 4 Â 10 5 (as indicated) in 100 ml Dulbecco's modified Eagle's medium (DMEM).
In all vaccination experiments, blood samples were taken from all the animals and pooled for the same group at each timepoint. The samples were taken on days À 22 (before any manipulation of the animals, serving as base level or control in each group), À 1 (the day before tumor implantation) and þ 15 (1 week after the third and last dose was administered). Plasma was obtained by centrifugation at 3000 r.p.m. 
Characterization of Tregs by confocal microscopy
In each group, the lymphocytes were stained with mouse Treg staining kit #2 (eBioscience, San Diego, CA, USA). Following the manufacturer's instructions, after staining, the cells were moved to LabTek Chambers for confocal microscopy, where 3 ml Hoechst 1 mg ml (Invitrogen, Carlsbad, CA, USA) per well was added, incubating 3 min in darkness, to allow contrast staining. Then the cells were scanned with a confocal microscope (Leica TCS-SP2, Barcelona, Spain) with argon and helium-neon lasers, fitted to an inverted microscope (Leica DM1R13). Finally, the number of cells per field of each of the stainings were counted, taking between 5 and 10 different fields at random from each sample, and preparing images overlap using the LCS Lite (Leica) software.
Statistical analysis
Statistical comparison of the tumor growth inhibition results in the different treatment groups was based on two-tailed analysis of variance with Bonferroni post hoc testing (95% confidence interval). The same test was applied to the results of the ELISA assays.
Significance in relation to survival was analyzed using the Kaplan-Meier survival curves and the log-rank nonparametric test.
All the tests and plots were performed with the Graph Pad Prism 4 package (San Diego, CA, USA).
RESULTS

Preventive vaccination
In our preventive model vaccine, we injected the mice with 10 Figure 1 . This figure shows that the best results were obtained in the B16-GM-CSF group (marked with an arrow in the figure), where development of the implanted tumor was not visible during the measurement period-a time in which mice from other groups had already begun to die as a result of tumor development. The groups vaccinated with IL-12-producing cells always yielded poorer results than the groups vaccinated with GM-CSF-producing cells alone. The best results with IL-12-producing cells were achieved with 4 Â 10 5 GM-CSF þ IL-12-producing cells, which reached 95% of tumor growth delay versus the control group.
Survival curves are shown in Figure 2 . Generally, the curves were consistent with the results of tumor growth inhibition, whereby the groups with smaller tumor sizes survived longer. This fact can be noted clearly in the B16-GM-CSF group, where the tumor was not initially detectable, and survival of the animals was 100% 46 months after tumor introduction. Groups with IL-12 reached only 60% survival. B16* and p2FØ groups were not differentiated from the control group. The group treated with IL-12-producing cells achieved statistically significant differences with respect to the controls (Po0.05). The three groups that included GM-CSF-producing cells similarly reached statistically significant differences with respect to the controls (Po0.005).
The results referred to specific anti-TMP (TMPs extract from B16 cells) IgG are shown in Table 1 , where groups that produced GM-CSF reached a higher production of IgG. The B16-IL-12 group yielded a lower production of IgG than groups with GM-CSF alone, and the combination of both cytokines did not exceed the effect achieved with GM-CSF alone, as shown in Table 1 . Groups with GM-CSF showed a less abrupt change between the production of IgG on day À 1 and day 15, so it seems that GM-CSF induces earlier stimulation.
The IgG subtypes also offered the same overall results as total IgG. Transfection with GM-CSF contributed to the humoral antitumor response in a meaningful way, whereas isolated IL-12 produced a weaker effect.
Tumor re-exposure: verification of antitumor immune memory. One year after the beginning of the previously described experiment, we rechallenged the surviving mice once again with the same tumor, to determine whether the immune response that had been established, and which allowed them to survive, had generated enough immunological memory to protect them from a second exposure to the tumor.
The experiment started with only one vaccine dose 14 days before tumor injection (10 5 B16 cells, in the left leg) with transfected cells in the surviving animals. We used new healthy animals as control group (n ¼ 5), with an age similar to that of the survivors of the previous experiment (approximately 14 months).
All the treated mice survived second tumor implantation. All of them died of old age as confirmed by necropsy study. However, all the controls had died by day 29 after tumor exposure. The three usual blood samples were also taken in this experiment to evaluate total IgG production and the production of subtypes IgG1 and IgG2a. The immune response of the surviving animals was faster and more powerful after this second exposure to the tumor, which demonstrates an effective IgG-mediated immunological memory response against the tumor. Figure 3 . All treatment groups achieved a difference with the highest degree of significance with respect to the control group, but the best treatment was GM-CSF combined with the IL-12 cytokine, at the dose of 2 Â 10 6 cells. The GM þ IL-12/2 group showed tumor growth inhibition 460% with respect to the control group. The groups treated with 2 Â 10 6 cells reached a greater delay in tumor growth than the groups treated with 0.5 Â 10 6 cells. The survival results are shown in Figure 4 . None of the animals reached overall survival, but the results in the treated groups were always better than those in the control group. The best results were achieved in the groups treated with 2 Â 10 6 cells. Only the GM þ IL-12/2 group reached statistically significant differences with respect to the controls (Po0.05).
The production of specific IgG against TMP in the therapeutic vaccination is shown in Table 2 . In relation to total IgG, the two groups that yielded the best survival results, having been treated with 2 Â 10 6 cells (GM-CSF and GM-CSF þ IL-12), also showed greater immunoglobulin production, which was particularly increased in the last two blood samples, collected on days 15 and 22, respectively. In the subtypes, the same groups show major production, with the particularity that in the case of IgG1, production in the first two blood samples ( À 1 to 8 days) was not detected. 6 cells were quite poor (results not shown), with the best group (B16-IL-12) reaching only 25% tumor growth inhibition with respect to the control group, whereas the B16-GM-CSF þ IL-12 group vaccinated with 2 Â 10 6 cells had achieved almost 70% inhibition in the previous experiment. In this assay, only the B16-IL-12 group reached statistical significance with respect to the control group (Po0.001).
The best treatments with 0.5 Â 10 6 and 2 Â 10 6 transfected cells achieved approximately 12 and 430 days of delayed mortality versus the control group, respectively. When the cell dose was increased to 8 Â 10 6 , a maximum delay of 5 days was obtained (GM-CSF), which was not sufficient to reach a statistically significant difference with respect to the control group (results not shown).
Based on the results of this high cell dose therapeutic vaccine, we decided to determine whether Tregs were involved in failure of the antitumor immune response. To this effect, we conducted a confocal microscopy study of Treg cells in the peripheral blood of treated animals. Counts of various fields (5-10 fields per treatment group) chosen at random were able to identify CD4 þ and CD8 þ T cells and 'classical' Treg cells (CD4 þ CD25 þ Foxp3 þ ). We did not find statistically significant differences among the different groups in terms of the Treg population. An additional subpopulation showing CD4-CD25 þ Foxp3 þ staining was also identified.
The confocal microscopy image shown in Figure 5 illustrates the different types of cells identified.
DISCUSSION
In this work, we study the possible synergy between the cytokines GM-CSF and IL-12 in a preventive and therapeutic tumor vaccine model using genetically modified tumor cells. The results described in this work show that preventive vaccination achieved total efficacy in terms of tumor growth inhibition and animal survival. However, therapeutic vaccination was only partially After blood samples were taken from the animals on days -22, -1 and 15 with respect to the day of implantation of the tumor (day 0), and the plasma was obtained, the latter was used for the ELISA assay specific for total IgG and subtypes IgG1 and IgG2a against TMP. The treatment groups are described in Figure 1 . All groups showed significant differences versus the control as a minimum at days -1 and 15 (Po0.001). effective. Synergy between GM-CSF and IL-12 was only observed in the therapeutic vaccine model. In preventive vaccination, the group treated with GM-CSF-expressing cells was the most effective, whereas in therapeutic vaccination the groups treated with GM-CSF þ IL-12-expressing cells were the most effective.
In the preventive vaccine, two doses were administrated before tumor injection. The best results were obtained in the B16-GM-CSF group, achieving total tumor growth inhibition and 100% animal survival. These results are consistent with those previously achieved by others and by our own group. 6, 7 Groups treated with cells transfected with il-12 and il-12 þ gm-csf achieved 60% survival. In view of these results, we decided to study IgG immunoglobulin switching to confirm immunological memory. We observed a statistically significant increase in the production of IgG in all vaccinated groups with respect to the controls. In this model, there was no synergistic effect between GM-CSF and IL-12. This was possibly due to an insufficient dose of these cytokines. We checked that gene expression is approximately 50% less in the bicistronic plasmid when containing two genes than when containing only one gene.
A year after these experiments, the animals that had survived were rechallenged with the tumor, receiving only one previous vaccine dose. All vaccinated animals survived this second tumor introduction, remaining free of B16 tumor until natural death. In the vaccine groups, IgG production was greater than in the control group, and the net production reached higher values at tumor reimplantation compared with the first levels, 1 year earlier. These results confirmed the idea that tumor protection is durable in time.
Following success with the preventive vaccines, we developed a model closer to the real situation found in clinical practice: therapeutic vaccination. In this study, we recorded a delay in tumor growth, but did not observe improvements in overall survival. The group vaccinated with 2 Â 10 6 irradiated cells transfected with gm-csf þ il-12 (B16-GM þ IL-12/2) reached the highest tumor growth inhibition (70% versus the control group). This group also showed a significant difference in the survival of animals, which was not recorded in any other case. These results suggest that there is some kind of synergy between GM-CSF and IL-12 in this therapeutic vaccine. [22] [23] [24] Unfortunately, in the treatment with low cell dosing we did not include the B16-IL-12 group, because of the poor results obtained with this group in the preventive vaccination. However, in the treatment with 8 Â 10 6 cells we decided to include this group again because in the experiment with low cell dosing the B16-GM-CSF þ IL-12/2 group was the group that obtained the best results. In the treatment with 8 Â 10 6 cells per dose, the results were very poor. Only the B16-IL-12 group achieved 25% tumor growth inhibition compared with the control group, the difference being statistically significant, but this did not increase animal survival. This high cell dose proved more ineffective than two million cells.
These results and those of other groups suggest that perhaps the immune response elicited by the vaccine was being surpassed by some inhibiting system. In recent years, many studies have published that this inhibitory system could comprise the Tregs. [29] [30] [31] In an attempt to increase the effectiveness of vaccines, avoiding the limitation created by tolerance, depletion of classical Treg cells has been chosen in many studies, using cyclophosphamide or specific monoclonal antibodies such as anti-CD25 32-34 and anti-CTLA4. 4, 35, 36 In order to understand these immunosuppressive phenomena in our model, we decided to study Treg cell variation in our highdose therapeutic vaccine with high dose, that is, that yielding the poorer results, and therefore possibly suffering inhibition of the antitumor response. From blood samples, we proceeded to identify Treg cells using confocal microscopy. No variations in classical Treg cell percentages (CD4 þ CD25 þ Foxp3 þ ) were observed among groups in our model. However, we identified a CD4-CD25 þ Foxp3 þ and a CD4-CD25-Foxp3 þ cell population. These populations may belong to the subset of CD8 Tregs, 27, 37 or to other types of regulatory populations such as for example myeloid suppressor cells, as proposed by other authors. 38, 39 New functional experiments blocking Treg response would be necessary to clearly define which population is responsible for the suppressor phenomena in our model.
